A fresh $1.5M in Series A funding is heading to Xeris Pharmaceuticals, Inc., a biopharmaceutical company focused on improving patient lives. The growth-oriented firm develops and commercializes advanced products across a range of therapies.

Get the full Xeris Pharmaceuticals, Inc. company profile
Access contacts, investors, buying signals & more
A fresh $1.5M in Series A funding is heading to Xeris Pharmaceuticals, Inc., a biopharmaceutical company focused on improving patient lives. The growth-oriented firm develops and commercializes advanced products across a range of therapies.
Portfolio company of VentureWell

KymaThera
KymaThera combines deep scientific insights with disciplined execution to build best-in-class precision medicines. Its accomplished research team has discovered multiple approved medicines to treat cancer and other serious diseases. Drawing on decades of collective drug discovery experience, KymaThera applies a proprietary framework for strategic structure-based drug design to create differentiated small-molecule therapeutics for better patient outcomes.
$80.0M Series b
today

Blaze Energy Technologies
We are shaping the future of maritime shipping by enabling vessels to run on any alternative fuel. By delivering fuel flexibility for both existing fleets and newbuilds, we eliminate fuel lock-in and empower operators to control their fuel strategy and costs.
$6.5M Seed
today
Largest funding rounds in Biotechnology on Signalbase right now.
| # | Company | Round | Amount | Date |
|---|---|---|---|---|
| 1 | ![]() Shockwave Medical United States | Unknown | $13.1B | 2y ago |
| 2 | ![]() NeuroEM Therapeutics United States | Unknown |
Companies that recently closed a Series a round.
| # | Company | Round | Amount | Date |
|---|---|---|---|---|
| 1 | ![]() Moving Doors Cyprus | Series a | $7.0M | today |
| 2 | ![]() Valarian United Kingdom | Series a | $50.0M | today |
| 3 |

Ghost
The world has changed, and media is struggling to change with it. The internet fuelled advertising-driven business models where all that mattered was capturing as many eyeballs as possible. The resulting economy brought us clickbait, outrage, fake news, and a fraught competition for your attention. Today, creators are choosing a new model where they have a direct relationship with an audience who pay a subscription to receive their content. The incentives are aligned, and the audience is the customer, not the product being sold. At Ghost, we're a small team creating a large platform that's redefining how people are publishing online. The opportunity ahead for subscription commerce is hard to overstate, and we're looking for people who can help turn our dream for the future of publishing into a reality.
$11.0M Seed
today
| $7.2B |
| 2y ago |
| 3 | ![]() GRAIL United States | Unknown | $7.1B | 2y ago |
| 4 | ![]() Illumina United States | Unknown | $7.1B | 2y ago |
| 5 | ![]() RemeGen Biosciences United States | Grant | $5.6B | 8mo ago |
![]() FLAI |
| Series a |
| $27.0M |
| today |
| 4 | ![]() Reuse Estonia | Series a | $20.3M | today |
| 5 | ![]() Flai Slovenia | Series a | $27.0M | today |
Contacts, investors, buying intent signals & tech stack.
Trusted by 200+ sales teams
See who invested in Xeris Pharmaceuticals, Inc. and reach their contacts directly.
Start free trialCarissa H.
Senior Director, Marketing Strategy
Mike M.
Regional Business Director, Rare Disease (Endocrinology)
Unlock 8 more key decision-makers at Xeris Pharmaceuticals, Inc. with verified emails and LinkedIn.
Start free trial
TuDOC
Recently received

Shyld AI
Recently received

Cardia, Inc.
Recently received